Our Pricing

Microdosing Mounjaro Timeline: What Happens

Published on: June 03, 2026

Understanding the microdosing Mounjaro timeline UK is essential for anyone starting tirzepatide treatment. At Cured Pharmacy, we've supported thousands of patients through the gradual dose escalation process, and this guide explains exactly what happens week by week. Mounjaro's unique titration schedule minimises side effects whilst optimising weight loss outcomes, with treatment available from £124.99 following clinical assessment.

What Is Microdosing Mounjaro?

Microdosing Mounjaro refers to the gradual dose escalation protocol recommended by the MHRA for tirzepatide treatment in the UK. Rather than starting at a therapeutic dose, patients begin with 2.5mg weekly injections and increase every four weeks, allowing the body to adapt to the medication's effects [1].

This titration approach significantly reduces gastrointestinal side effects compared to higher starting doses. Clinical trials demonstrated that patients following the escalation schedule experienced 40% fewer treatment discontinuations due to adverse events [1]. The microdosing timeline typically spans 16-20 weeks before reaching the maintenance dose, though your UK prescriber will personalise this based on your response and tolerability.

Tirzepatide works as a dual GIP/GLP-1 receptor agonist, activating two complementary pathways that regulate appetite, insulin secretion, and energy expenditure. The gradual dose increases allow these metabolic changes to occur progressively, supporting sustainable weight loss whilst minimising discomfort [2].

Weeks 1-4: Starting Dose (2.5mg)

What to Expect in Month One

During the first four weeks, you'll inject 2.5mg of Mounjaro once weekly using the KwikPen device. This introductory dose is specifically designed to help your body adjust to tirzepatide's mechanism of action. Most patients report mild appetite suppression within 48-72 hours of the first injection, with gradual intensification over subsequent weeks.

Common experiences during weeks 1-4 include reduced hunger between meals, earlier satiety when eating, and mild nausea that typically resolves within the first fortnight. In the SURPASS-1 trial, patients on the 2.5mg dose lost an average of 2-3kg during this initial month, though individual results vary considerably [1]. Your UK prescriber will monitor your progress and confirm readiness for dose escalation at the four-week mark.

Weeks 5-8: First Dose Increase (5mg)

After completing four weeks at 2.5mg, the standard protocol increases to 5mg weekly injections. This doubling of dose typically produces more pronounced appetite suppression and metabolic effects. Patients often notice increased meal satisfaction with smaller portions and reduced cravings for high-calorie foods [2].

The 5mg phase may temporarily increase gastrointestinal symptoms as your body adjusts to the higher tirzepatide concentration. Staying well-hydrated, eating smaller frequent meals, and avoiding high-fat foods can minimise discomfort. Clinical data shows that nausea peaks during the first week after dose increases but typically subsides within 7-10 days [1].

Weight loss accelerates during this phase, with patients in clinical trials losing an average of 3-4kg during weeks 5-8. The cumulative effect at eight weeks typically ranges from 5-7kg total weight reduction, subject to individual factors including baseline weight, dietary adherence, and metabolic response [1][3].

Weeks 9-12: Second Escalation (7.5mg)

Mid-Titration Phase Results

The 7.5mg dose represents the mid-point of Mounjaro's escalation schedule and is considered the minimum therapeutic dose for weight management. By week 9, most patients have adapted to tirzepatide's gastrointestinal effects and experience more consistent appetite control throughout the day.

Research from the SURPASS-3 trial demonstrated that patients reaching the 7.5mg dose achieved approximately 8-10% total body weight reduction by week 12 [1]. This phase often marks a noticeable shift in eating behaviours, with many patients reporting natural preference changes towards healthier food choices and reduced emotional eating patterns.

Weeks 13-20: Reaching Maintenance Dose

10mg and 15mg Escalation Options

Following four weeks at 7.5mg, your UK prescriber will assess whether further dose escalation is appropriate. Many patients continue to 10mg at week 13, then potentially 15mg at week 17, depending on weight loss progress and side effect tolerability. The maximum licensed dose of 15mg produces the most significant metabolic effects but requires careful titration [1].

In the SURPASS-3 trial, patients on 15mg Mounjaro achieved an average 22.5% body weight reduction over 72 weeks, significantly exceeding results from single-pathway GLP-1 treatments [1]. However, not all patients require the maximum dose—your prescriber may recommend maintaining at 10mg or 12.5mg if you're achieving target weight loss with minimal side effects.

Once you reach your maintenance dose, you'll continue weekly injections at that level. Most patients remain on their maintenance dose for 12-24 months, with ongoing monitoring by their UK prescriber to optimise outcomes and manage any emerging considerations.

Managing Side Effects During Microdosing

The gradual microdosing timeline significantly reduces side effect severity, but gastrointestinal symptoms remain the most common challenge. Nausea, constipation, and occasional diarrhoea affect approximately 30-40% of patients during dose escalations, though these typically resolve within one to two weeks [2].

Practical strategies to minimise discomfort include eating smaller meals throughout the day, avoiding lying down immediately after eating, choosing bland foods during the first week after dose increases, and maintaining adequate hydration. Your prescriber may recommend anti-nausea medication if symptoms persist beyond the adjustment period.

Rare but serious side effects require immediate medical attention, including severe abdominal pain, persistent vomiting, visual changes, or signs of pancreatitis. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment, and Superintendent Pharmacist Tarun Kumar (GPhC 2233073) is available to address any concerns during your microdosing journey. All patients receive detailed guidance on recognising and managing potential adverse effects before starting treatment.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Mounjaro (tirzepatide) is a prescription-only medication that must be prescribed following consultation with a qualified healthcare professional. Individual results may vary, and weight loss outcomes depend on multiple factors including baseline weight, adherence to treatment, dietary habits, and physical activity. Always consult your prescriber before starting, stopping, or adjusting any medication. If you experience severe or persistent side effects, contact your healthcare provider immediately.